Cini John
Family · Houston, TXNPI 1528590288
Payments from drug & device makers
Across 1,152 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$2K
- Novo Nordisk$2K
- Amgen$1K
- GSK$1K
- Boehringer Ingelheim$1K
- plus $11K from 54 others
What the payments were for
- Consulting fees$1751%
- Food & beverage$21,54399%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,832 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 315 | $305,857 |
| JardianceEmpagliflozin | 231 | $266,493 |
| OzempicSemaglutide | 125 | $160,891 |
| ProliaDenosumab | 68 | $118,038 |
| JanuviaSitagliptin Phosphate | 85 | $96,523 |
| XareltoRivaroxaban | 103 | $94,701 |
| VascepaIcosapent Ethyl | 120 | $91,241 |
| LinzessLinaclotide | 105 | $77,705 |
| TrulicityDulaglutide | 47 | $70,595 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $69,097 |
| MyrbetriqMirabegron | 74 | $51,420 |
| KerendiaFinerenone | 61 | $45,527 |
| EliquisApixaban | 43 | $45,061 |
| TradjentaLinagliptin | 35 | $39,609 |
| VemlidyTenofovir Alafenamide | 23 | $32,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $1,155 | $321,410278 claims |
| AstraZenecaFarxiga, Symbicort | $2,172 | $313,763334 claims |
| Novo NordiskOzempic, Rybelsus | $1,846 | $188,976144 claims |
| AbbVieLinzess, Ubrelvy, Restasis, Namzaric | $2,792 | $126,460153 claims |
| AmgenProlia | $1,321 | $118,03868 claims |
| MerckJanuvia, Janumet Xr | $194 | $104,290100 claims |
| Johnson & JohnsonXarelto | $242 | $94,701103 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,209 | $93,247114 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $806 | $88,32560 claims |
| Astellas Pharma US IncMyrbetriq | $337 | $51,42074 claims |
| BayerKerendia | $1,139 | $45,52761 claims |
| PfizerEliquis | $239 | $45,06143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Houston
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- David WeirDallas$959K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.